Arcturus Therapeutics(ARCT)
Search documents
Arcturus Therapeutics(ARCT) - 2021 Q1 - Earnings Call Transcript
2021-05-11 02:44
Arcturus Therapeutics Holdings, Inc. (NASDAQ:ARCT) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Neda Safarzadeh – Head of Investor Relations, Public Relations and Marketing Joseph Payne – President and Chief Executive Officer Andy Sassine – Chief Financial Officer Steve Hughes – Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Yigal Nochomovitz – Citigroup Wangzhi Li – Ladenburg Shubhendu Sen Roy – Brookline Steven Seedhouse – Raymond James Y ...
Arcturus Therapeutics(ARCT) - 2020 Q4 - Earnings Call Transcript
2021-03-02 02:43
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET Company Participants Neda Safarzadeh - Head-Investor Relations, Public Relations & Marketing Joseph Payne - President & Chief Executive Officer Ooi Eng Eong - Deputy Director-Emerging Infectious Diseases Programme-Duke-NUS Medical School & Arcturus Vaccine Platform Scientific-Advisory Board Steve Hughes - Chief Medical Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Off ...
Arcturus Therapeutics(ARCT) - 2020 Q3 - Earnings Call Transcript
2020-11-10 03:30
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2020 Results Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Neda Safarzadeh - Head of Investor Relations, Public Relations & Marketing Joseph Payne - President & Chief Executive Officer Andy Sassine - Chief Financial Officer Steve Hughes - Chief Development Officer Conference Call Participants Seamus Fernandez - Guggenheim Madhu Kumar - Baird Yasmeen Rahimi - Piper Sandler Yigal Nochomovitz - Citigroup Steve Seedhouse - Raymond ...
Arcturus Therapeutics(ARCT) - 2020 Q3 - Quarterly Report
2020-11-09 21:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, par value $0.001 per share ARCT The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 | --- | --- | |------------------------------ ...